Albert Bourla, Pfizer CEO (Eric Risberg/AP Images)
Pfizer says IRA impact will be 'modest,' maps out R&D priority changes
Despite being an early critic of the Inflation Reduction Act, Pfizer told investors on Monday that the legislation is likely to have a “modest” impact …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
